Evidence map›Paper›PMID 36380383›Full record

Trial reportAIDS research and therapy2022

Predicting viral load suppression by self-reported adherence, pharmacy refill counts and real time medication monitoring among people living with HIV in Tanzania.

Kennedy M Ngowi, Linda Minja, I Marion Sumari-de Boer, Rob E Aarnoutse, Lyidia Masika, Mirjam A G Sprangers, Francis M Pima, Blandina T Mmbaga, Peter Reiss, Pythia T Nieuwkerk

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kennedy M NgowiKilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania. k.ngowi@kcri.ac.tz.
Linda MinjaKilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania.
I Marion Sumari-de BoerKilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania.
Rob E AarnoutseRadboudumc, Radboud Institute for Health Sciences and Department of Pharmacy, Nijmegen, The Netherlands.
Lyidia MasikaKilimanjaro Christian Medical Centre, Moshi, United Republic of Tanzania.
Mirjam A G SprangersDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Francis M PimaKilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania.
Blandina T MmbagaKilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania.
Peter ReissDepartment of Global Health, and Amsterdam Institute for Global Health and Development Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Pythia T NieuwkerkDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Kilimanjaro Christian Medical Centre · TZUniversity of Amsterdam · NLAmsterdam Institute for Global Health and Development · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMonitoring of adherence to antiretroviral treatment (ART) is of utmost importance to prevent treatment failure. Several measures to monitor adherence have been applied in low-resource settings and they all have pros and cons. Our objective was to examine whether any of the following adherence measures is a better predictor of participants' viral load suppression: (1) self-report, (2) pharmacy refill count, (3) Real Time Medication Monitoring (RTMM), (4) a combination of self-report and pharmacy refill count or (5) all three adherence assessment methods combined. METHODOLOGY: This was a post-hoc analysis of data from our 48-week REMIND-HIV randomized controlled trial in which adherence to ART was measured using self-report, pharmacy refill counts and RTMM among ART-experienced adults living with HIV subjectively judged to be nonadherent to ART. For each adherence measure, we calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for predicting virological failure defined as a viral load (VL) of > 20 copies/mL. To determine at which percentage of adherence the prediction was strongest, we evaluated adherence cut-offs of 80%, 85%, 90%, 95% and 100% using receiver operating characteristic (ROC) curves. VL data were obtained after 48 weeks of follow-up in the trial.

resultsA total of 233 people living with HIV (PLHIV) were included in this analysis. When comparing the ability of self-reported adherence with pharmacy refill count and RTMM adherence to predict viral load > 20 copies/ml, self-reported adherence had the lowest sensitivity, ranging from 6 to 17%, but the highest specificity, ranging from 100 to 86%, depending on cut-off values from 80 to 100%. Area under the ROC curves (AUC) were 0.54 for RTMM, 0.56 for pharmacy refill count and 0.52 for self-report, indicating low discriminatory capacity for each of the adherence measures. When we combined the self-report and pharmacy refill count measures, sensitivity increased, ranging from 28 to 57% but specificity decreased, ranging from 83 to 53%. When all three measures were combined, we observed the highest value of sensitivity, ranging from 46 to 92%, and PPV, ranging from 32 to 36%, at high cut-offs ranging from 80 to 100%. Upon combination of three adherence measures, the AUC increased to 0.59.

conclusionOur results show that adherence assessed exclusively by self-report, pharmacy refill count or RTMM were insufficiently sensitive to predict virologic failure. Sensitivity markedly improved by combining all three measures, but the practical feasibility of such an approach would need to be studied.

Indexed as

Anti-HIV AgentsHIV InfectionsPharmacyAdultAnti-Retroviral AgentsHumansMedication AdherenceSelf ReportTanzaniaViral LoadAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID36380383
PMCPMC9664713
OpenAlexW4309223607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.